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Background: There is a lack of practical research frameworks to guide the development of patient decision aids
[PtDAs]. This paper described how a PtDA was developed using the International Patient Decision Aids (IPDAS)
guideline and UK Medical Research Council (UKMRC) frameworks to support patients when making treatment
decisions in type 2 diabetes mellitus.
Methods: This study used mixed methods to develop a PtDA for use in a UK general practice setting. A 10-member
expert panel was convened to guide development and patients and clinicians were also interviewed individually using
semi-structured interview guides to identify their decisional needs. Current literature was reviewed systematically to
determine the best available evidence. The Ottawa Decision Support Framework was used to guide the presentation
of the information and value clarification exercise. An iterative draft-review-revise process by the research team and
review panel was conducted until the PtDA reached content and format ‘saturation’. The PtDA was then pilot-tested
by users in actual consultations to assess its acceptability and feasibility. The IPDAS and UKMRC frameworks were used
throughout to inform the development process.
Results: The PANDAs PtDA was developed systematically and iteratively. Patients and clinicians highlighted the needs
for information, decisional, emotional and social support, which were incorporated into the PtDA. The literature review
identified gaps in high quality evidence and variations in patient outcome reporting. The PtDA comprised five
components: background of the treatment options; pros and cons of each treatment option; value clarification
exercise; support needs; and readiness to decide.
Conclusions: This study has demonstrated the feasibility of combining the IPDAS and the UKMRC frameworks for the
development and evaluation of a PtDA. Future studies should test this model for developing PtDAs across different
decisions and healthcare contexts.
Keywords: Patient decision aids, Decision making, Diabetes mellitus, Insulin, Complex interventionBackground
Shared decision making is an important component of
patient-centred care [1]. It involves the exchange of in-
formation and negotiation between the patients and
healthcare professionals to reach a consensus on a par-
ticular decision [2]. The decision making process is com-
plex and different decision support interventions have
been developed to facilitate this process [3].
Patient decision aids (PtDAs) are ‘interventions de-
signed to help people make specific and deliberative
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unless otherwise stated.providing information on the options and outcomes rele-
vant to a person’s health status and implicit methods to
clarify values’ [4]. They are different from patient health
education materials which provide general health informa-
tion about specific medical conditions including diagnosis,
investigation and treatment. There are currently more
than 500 PtDAs that have been developed worldwide, mainly
in North America and Europe. [Decision Aids Library
Inventory http://decisionaid.ohri.ca].
The effectiveness and utility of a PtDA is dependent
on its quality. The International Patient Decision Aid
Standards (IPDAS) collaboration has identified appropriate
quality indicators using a Delphi consensus method and
this provides guidance on the assessment of the content,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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few PtDAs developers describe the development process
per se and, of those which do, there is a wide variation in
how PtDAs are actually developed. In addition, PtDAs are
often developed without users’ involvement [6].
Although the IPDAS guideline provides a framework
for the development of a PtDA, it does not provide guid-
ance on which research methods to use; neither does it
explicitly link the development of a PtDA to its evalu-
ation and implementation. It is, therefore, necessary to
combine these guidelines with other frameworks such as
that produced by the UK Medical Research Council
(UKMRC) framework which can link the development of
the PtDA to its evaluation and implementation (Figure 1)
[7,8]. It is designed to guide the development and evalu-
ation of complex interventions, such as PTDAs, and it
stresses the important role of evidence, theories and mod-
elling in the process of developing a complex intervention.
Specific research methods are recommended to operation-
alise each step and it was for this reason that UKMRC
Framework was used to complement the IPDAS guideline
to develop and evaluate the PDA described in this study.
In addition, the UKMRC framework highlights the im-
portance of having a range of options before deciding
which intervention to use and that it should be based on
existing best available evidence. Before developing a deci-
sion support tool, it is important to reflect whether PtDA
is the best tool to use to support decision making.
This paper described how the Patient and insulin
Decision Aids (PANDAs) PtDA was developed for people
with Type 2 Diabetes Mellitus [T2DM] based on the
IPDAS criteria and UKMRC framework. The PANDAs
study was conducted from 2007–2010 to develop the
PtDA and to evaluate its effectiveness in the UK general
practice [9].
Methods
We used a systematic and iterative approach to develop
the PtDA by incorporating the IPDAS and UKMRC frame-
work (Table 2). The UKMRC framework informed the
methods used for the development of the PtDA, which is
not stated in the IPDAS guideline. This section described
in detail how the methods proposed by the UKMRC
framework were used to operationalise each step: expert
consensus (e.g. drafting of the PtDA), literature review
(e.g. collating clinical evidence), individual interviews
(e.g. needs assessment) and questionnaire surveys (e.g. ac-
ceptability and feasibility) (Table 2). This part of the PANDAs
study was conducted in the general practice setting,
Sheffield, England in 2007–2008. We obtained ethics ap-
proval from the National Health Service Research Ethics
Committee (REC reference: 07/Q2308/53).
The members of the expert panel were selected based
on their experience as patients or involvement in thecare for people with type 2 diabetes in general practice
(Table 2). The expert panel was responsible for reviewing
the first and the subsequently revised drafts of the PtDA
produced by the research team. This expert panel assessed
the PtDA based on: (1) member’s experience as patients
who were making or who had made the decision about
starting insulin treatment; (2) healthcare professionals
who had helped patients in making such decisions; and
(3) key opinion leaders/policy makers who were involved
in implementing health services for diabetes in General
Practice. Members of the review panel comprised two pa-
tients, three healthcare professionals, three key opinion
leaders and three representatives from the local Primary
Care Trust and research network.
We conducted the literature review for two reasons;
firstly, we aimed to identify the effective decision sup-
port interventions tools that were available; secondly, we
wanted to search for latest clinical evidence on the pros
and cons of the different treatment options to be incor-
porated into the PtDA. Therefore, two systematic review
were conducted. As far as possible, we searched for sys-
tematic reviews and national or local clinical practice
guidelines. In the event that they were not available,
findings from individual studies were appraised, synthe-
sised and summarised. The quality of the information
was graded according to the “grading for evidence-based
rheumatology” guidelines [13].
A qualitative methodology using individual in-depth
interviews and focus group discussion was used for the
needs assessment, acceptability and feasibility studies. A
mixed methodology was used in this process to triangulate
the data so that the PtDA could cater for the comprehen-
sive needs of the users. Patients with type 2 diabetes who
were at the point of deciding whether or not to start insu-
lin therapy were recruited into the study. Healthcare pro-
fessionals, including general practitioners, practice nurses
and dieticians, who were involved in managing patients
with type 2 diabetes, were also included in the study. For
the needs assessment, the users were interviewed indi-
vidually for their needs when making (or facilitating) a de-
cision on insulin therapy. As for the feedback on the
acceptability and feasibility of using the PtDA, both the
patients and clinicians were interviewed after they had
used the PtDA at the consultation.
One of the researchers (CJN) conducted all the inter-
views using a semi-structured interview guides, which were
developed separately for patients and clinicians based on
the literature review and expert opinion (Additional files 1
and 2). The interviews were audio-recorded, transcribed
verbatim, checked and analysed using a thematic approach.
NVivo 7 software was used to manage the qualitative data.
In addition, a bespoke questionnaire was used to capture
quantitative feedback from the users on the acceptability
and feasibility of using the PtDA. The users provided
Table 1 Development of the PANDAs insulin PDA using the IPDAS collaboration framework [6]





• The information included in the PDA was based on two criteria:
○ What do patients want to know before making a decision
○ What do patients need to know before making a decision?
• The findings from the needs assessment of the patients informed what and how much they
wanted to know before making a decision
2. Presenting probabilities Development
(content)
• The “risk communication” section of the PDA was based on the decision making theories
○ Use of event rates specified by the population in period (e.g. number of people affected
out of 100 people over 5 years)
○ Comparison of outcomes probabilities using the same denominator, period, scale (e.g. out
of 100 people over 5 years)
○ Description of the uncertainty around probabilities (‘platinum’, ‘gold’, ‘silver’ and ‘bronze’)
• Visual diagrams (“smiley” faces) were used in conjunction with other methods to illustrate
the probabilities (words, numbers, diagram)
• ‘Smiley’ sticker was used to present individualised risk to patients based on their HbA1c




• Values may be attributed to
○ Each treatment option (e.g. values attributed to “make no change”, “more adherent to
existing treatment” and “ starting insulin”)
○ Specific features of the treatment option i.e. the value of the procedure/process
(e.g. the values associated with insulin injection)
○ Value of outcomes (e.g. the values associated with weight gain due to insulin treatment)
○ Value of probabilities (e.g. the values associated with the probabilities of gaining 6-8 lbs
in weight over a year with insulin treatment).
• The PANDAs insulin PDA helped patients to clarify their own values using an explicit
approach
• Patients worked through a personal worksheet in the PDA to determine how important






• IPDAS quality criteria recommend that PDAs should:
○ Provide steps to make a decision
○ Suggest ways to talk about the decision with a health professional
○ Include tools (e.g. workshop question list) to discuss options with others.
• The PANDAs PDA
○ Provides a five-step systematic approach to decision making (Table 3)
○ Encourages the patient to discuss uncertainties or queries with the healthcare
professionals (prompts)
○ Encourages the patient to write down their questions for the healthcare professionals








• PANDAs insulin PDA provided balanced information by
○ Making comparison of the positive and negative features of each option
○ Both features were presented with equal detail and in the same format (font, order,
display of statistic)
• The balance of the PDA was assessed during the acceptability study by asking the patients and
the healthcare professionals how balanced and fair they found the information presented




• The PANDAs insulin PDA used “Simply Put” plain language guideline produced by the
Centre for Communicable Disease and Prevention (1999).
• The “readability” was assessed using the Readability Calculations, version 7.0 software
(which includes the SMOG and FRY readability tests)
• Patients and patient education experts also reviewed the PDA
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Table 1 Development of the PANDAs insulin PDA using the IPDAS collaboration framework [6] (Continued)
8. Basing information on up
to date scientific evidence
Development
(content/process)
• Where possible, clinical evidence based on systematic reviews and national or local clinical
practice guidelines were used.
9. Establishing effectiveness Evaluation
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usability of the PtDA using a five-point Likert scale.
Results
UKMRC and IPDAS frameworks
Table 3 demonstrated step-by-step how the findings from
the needs assessment study, clinical evidence and the ODSF
were incorporated into the development of the PtDA using
the UKMRC framework. Both the UKMRC framework and
IPDAS guideline guided the initial stages of the develop-
ment of the PANDAs PtDA which included: convening an
expert panel, comprising key stakeholders; conducting a
needs assessment study; and searching for evidence for de-
cision support interventions. The UKMRC framework
highlights the importance of using theories to inform the
development of complex interventions and is used to iden-
tify appropriate decision making theories. The drafting and
piloting of the PtDA was also an important step in the
UKMRC framework. The IPDAS framework guided the
content and format development of the PtDA (Table 2).
Convening an expert panel
Initially, development and expert panels were convened to
inform and advise on the development and evaluation ofFeasibility and piloting
- Testing procedure (alp
patients and general p
- Estimating recruitment
- Determining sample si
Development
- Needs assessment (patients, clinicians)
- Evidence (e.g NICE guidelines, RCTs)





- Surveillance and m
- Lon term follow up
Figure 1 Modification of the UKMRC framework for the developmentthe PtDA. The development panel members were three
healthcare professionals (2 GPs and a clinical nurse spe-
cialist in diabetes), one patient educator, three experts in
decision science, two experts in evidence-based medicine
and three experts in research methodology who had ex-
tensive experience in qualitative, quantitative and mixed
methodologies. They were responsible for assessing the
appropriateness of the research methodology used in the
development and evaluation of the PtDA which informed
the design and data analysis of the needs assessment ac-
ceptability and feasibility studies.
Needs assessment
The needs assessment study identified four main needs
common to both patients and clinicians: decisional, infor-
mation, emotional and social support needs. For example,
the patients wanted information on different treatment
options available (besides insulin), the benefits and side ef-
fects of insulin therapy, and the impact of starting insulin
on their lives. This information was incorporated into the
PtDA. Although the PtDA did not address patients’ social
and emotional needs directly, they were highlighted to the
healthcare professionals who would address them during
the consultation.ha and beta test with 
ractitioners)




- Understanding change process
- Assessing cost effectiveness
onitoring
and evaluation of complex interventions [7].
Table 2 The development process of the PANDAs insulin PDA
Steps Framework Objectives Methods Outcome
1. Convene an expert
panel
UKMRC/IPDAS • To guide the development of the PDA, including
determining the clinical focus, needs assessment,
research methods, content and format of the PDA,
as well as evaluation and implementation
• Expert consensus
(face-to-face meetings)
• Ten stakeholders were selected, including general practitioners,
diabetologist, diabetes educator, expert patients, representative
from Diabetes UK, patient decision support experts, statistician
• Four meetings were conducted during the one-year period
2. Assess users’ needs UKMRC/ IPDAS • To assess the needs of patients with type 2
diabetes who are making treatment decisions
• Individual patient and
clinician interviews
• Nine patients at the point of decision making and 14 general
practitioners, nurses and dieticians involved in diabetes care
were interviewed
• To assess the needs of clinicians who are
supporting patients’ decision making
• The users identify decisional, emotional, information and
social support needs
• To determine the preferred decision support tool
and its mode of delivery
• A paper-based decision support tool is preferred
3. Review the literature UKMRC/ IPDAS • To identify the range of effective decision support
tools (general)
• Literature review • PDA was selected as the decision support tool with the most
evidence [10]
• Identify existing decision support tool for diabetes
treatment (specific)




UKMRC • To review the existing decision support theories • Literature review • Ottawa decision support framework was selected as it was
the most used and implemented [11]
5. Collate the clinical
evidence for treatment
options
IPDAS • To search, select and synthesise the evidence of
the pros and cons of the treatment options
• Literature review, focusing
on systematic reviews and
local/national clinical practice
guidelines
• There was a lack of systematic reviews on the efficacy and
safety of insulin vs oral oral hypoglycaemic agents. Evidence
was synthesized from cohort studies [12]
6. Drafting of the PDA
(Alpha testing I)
IPDAS/UKMRC • The design the PDA (content and format) team
and PDA design expert drafted the PDA iteratively
• Draft-review-revise iterative
process by the research team
and PDA design experts
• The preliminary draft of the PDA was developed based on
the IPDAS criteria and went through 13 iterations between
the researchers and PDA design experts
7. Review by the expert
panel (Alpha testing II)
IPDAS/UKMRC • To review the PDA by the stakeholders (not part
of research team)
• Expert panel consensus
(meetings and emails)
• The research team and the PDA design experts discussed the
feedback and agreed on the final draft for beta testing
8. Develop the PDA
training module
for clinicians
• To develop a training module, including a
guidebook and workshop, to guide clinicians on
how to use the PDA with the patients
• Expert consensus involving
research team, decision support
experts, diabetes educator and
medical education expert
• A PDA guidebook for clinicians
• A 1-2 hour workshop involving short lectures, demonstration
and feedback
9. Assess the readability IPDAS • To assess the readability of the PDA • Readability Calculations v7.0
software
• The readability was at grade 8 (or English year 9) using SMOG
and Fry
10. Review by patients
and clinicians (Beta testing)
IPDAS • To assess the acceptability and feasibility of the
PDA in real consultations
• Patient and clinician
questionnaire survey
• Nine patients and 14 clinicians found the PDA acceptable
and feasible
• Individual interviews with
patients and clinicians
11. Finalise the PDA IPDAS • To finalise the content, design and quantity to be
printed
• Research team and PDA
design expert consensus
• A 16-paged paper PDA was developed





















Table 3 The development of the PANDAs insulin PtDA based on needs, evidence and theory
Five steps in
decision making
Description Needs based Evidence based Theory based
1. Background
information
• This section aims to provide information
about the decision of starting insulin; how
diabetes could affect the patient personally;
adherence to current diabetes treatment; and
the range of treatment options available.
• In the needs assessment study, the patients
wanted and the clinicians felt that the
patients needed information on: insulin and
its pros and cons; particularly the impact on
their lives, symptoms, long term
complications,
• The information on the benefits
and risks of insulin was based
on the NICE guidelines [14],
UKPDS study [12]
• The ODSF proposed that patients should be
‘knowledgeable about the issues (of treatment)’
so that they would make an informed decision.
• ‘Make no change’ was rarely offered to the
patients; the healthcare professionals
recognised that this was an option some
patients preferred.
• A description of insulin therapy, pros and
cons, its impact on quality of life, in sufficient
detail during the first part of the PtDA would
familiarise patients who were previously
unfamiliar with the decision [15].
2. Learn about
the choices
• This section describes each of the three
treatment choices in detail, including the
advantages and disadvantages of each
option
• The selection of the information regarding
the advantages and disadvantages of each
treatment options was based the patients’
decisional needs and what the healthcare
professionals felt was important for the
patient to know before making the
decision.
• The evidence used in this
section (diabetic complications,
hypoglycaemia, weight gain)
were derived from best
available evidence.
• Two theories were used when developing
this section of the PtDA: the ‘theory of
expected utility’ and the ‘prospect theory’.
• The patients’ chance of getting diabetic
complications is personalised according to
their HbA1c.
• However, the strength of
available evidence varied and
this was reflected in the
‘evidence battery indicator’.
• The outcome probabilities presented in this
PtDA include the risk of diabetic complications
and the chance of experiencing the side
effects of insulin.
• The level of evidence is graded and
presented as ‘number of bars in a battery’.
• The risk of complications of poor
glycaemic control is personalised
according to patients’ individual HbA1c.
• The risk of diabetic complications is presented
both as the chance of the patient ‘getting the
complications’ (‘negative framing’) as well as





• This section clarifies patients’ values attached
to the attributes of each treatment option.
• The patients had expressed the need for
the healthcare professionals to address
their concerns about insulin injections and
the side effects.
• The ODSF proposes the importance of
supporting patients in clarifying their values
to ensure that the treatment option patients
choose are in congruence with what is
important to them (values).
• They were asked to indicate whether the
reasons for ‘choosing insulin’ and ‘not
choosing insulin’ were important to them.
• This section on value clarification helped
the healthcare professionals to understand
patients’ values and priorities.
• The ‘reasons for choosing insulin’ reflected
what the healthcare professionals felt was
necessary for the patients to be aware of
before making their decision.
• The ‘value clarification exercise’ in this PtDA
focuses on the values related to the
advantages and disadvantages of starting or
not starting insulin.
4. What else do
you need to help
you make a
decision?
• This section explores the support the patient
needs before including information, values,
support from the family and clinician, and
certainty about the diagnosis
• The patients wanted the healthcare
professional to address their concerns
about the treatment options before
making a decision.
• The ODSF postulates that a PtDA should
address patients’ decisional needs which
include: balanced and accurate information;
clarity about values associated with the
treatment options; support from healthcare
professionals, family and friends to reduce
their decisional conflict.
• The healthcare professionals wanted to






















Table 3 The development of the PANDAs insulin PtDA based on needs, evidence and theory (Continued)
• This section was designed to help bridge
this gap by allowing the patients to
communicate their concerns to the
healthcare professionals effectively.
• This section of the PtDA was developed
based on this theoretical framework.
5. What’s next? • This is the final step and it asks the patients
to indicate whether they are ready to make
a decision and, if so, which option they
preferred.
• For those who chose‘ add insulin’ as the
option, they would complete an additional
section which explored: their motivation;






















Figure 2 An illustration of the PANDAs patient decision aid.
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Durand [11] identified a range of decision making theories
that have been used to develop PtDAs, out of which, the
Ottawa Decision Support Framework (ODSF) was the most
commonly used and implemented. The ODSF is a concep-
tual framework which consists of a few theories such as ex-
pected utility theory, decisional conflict theory and social
support theory [16]. The PANDAs PtDA was developed
based on the ODSF, which postulates that by identifying an
individual patient’s decisional needs, a PtDA can provide
personalised decision support to patients, and help patients
make an informed and value-based decision about their
health which in turn leads to a better health outcome ie.
improved decisional quality [17] (Figure 2). The ‘decisional
needs’ highlighted in the ODSF, such as decisional conflict,
values, knowledge, expectations and support, were incorpo-
rated into the PANDAs PtDA.
Collate background information and clinical evidence
The background information and clinical evidence in-
cluded in the PtDA was based on the needs of the patients
and the healthcare professionals; availability and quality of
the evidence; and the relevance to the local population.
The evidence regarding the outcome probabilities for each
of the treatment options was not easily available. A sys-
tematic review of the literature was, therefore, carried out
to search, appraise and synthesise the information neces-
sary to be incorporated into the PtDA.
We searched the literature systematically to determine
the effectiveness of insulin-oral glucose-lowering drugs
combination in reducing HbA1c, diabetic symptoms, dia-
betic complications and death compared to oral glucose-
lowering drugs alone; its safety profile and the level of
reduction in HbA1c. We included: systematic review,
randomised and non-randomised trials; controlled and
uncontrolled trials; cohort study. The inclusion criteria for
the participants were: people with type 2 diabetes; blood
sugar was not well controlled despite taking maximum
oral glucose-lowering drugs; and insulin-naive. Two elec-
tronic databases, Cochrane Trials Register and Medline,
were searched for eligible studies from 1950 to 2006. In
addition, the reference lists and bibliographies of all rele-
vant papers were searched for additional studies using the
‘snowballing’ method. This was performed on key articles
till ‘reference saturation’. Publications by key authors were
also searched and they were contacted for unpublished
data. Only English-language publications were included in
this review.
For the electronic database search, the following terms
and strategy were used: diabetes mellitus, type 2, insulin,
thirst, weight loss, weight gain, polyuria, nocturia, fatigue,
infection, vision disorders, haemoglobin A, glycosylated,
blood glucose, diabetes complications, mortality, death,
mortality, hypoglycaemia, weight gain, lipodystrophy
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the identified studies. Where a clear decision could not
be made on the basis of the title or the abstract, the
study was considered relevant. Full text of all relevant
studies was retrieved. The method sections of the re-
trieved articles were examined to assess whether they
satisfied the inclusion criteria; uncertainty was resolved
by asking a co-researcher for independent assessment.
Drafting of the PtDA
The initial drafts of the PtDA were developed by the re-
search team based on the IPDAS guideline [5] and the
ODSF [16]. It went through a number of iterations be-
fore it was ready for alpha testing (Table 2).
Alpha testing
In line with the IPDAS recommendations, the PtDA draft
was reviewed by the review panel before being revised by
the research team. This phase in the development of the
PtDA was iterative and repeated until no new comments
emerged, ie it had reached “thematic saturation” (Table 2).
Assessing readability
The IPDAS guideline recommends that PtDAs should be
‘written at a level that can be understood by the majority
of patients in the target group’ and it sets the readability
threshold at grade 8 (English year 9) using readability test
such as SMOG or Fry [6]. The readability of this PtDA
was measured using the Readability Calculations v. 7.0
software (Micro Power & Light Co. of Dallas, Texas 2005)
and the results showed SMOG score at grade 7.
Beta testing
During the development of the PtDA, the PtDA drafts
underwent three cycles of review by the users (nine pa-
tients and 14 healthcare professionals in total) and the
expert panel as well as revisions by the research team.
All members of the expert panel felt that the PtDA was
acceptable in terms of content, format and readability
prior to its’ use in clinical practice.
In the initial feasibility study, the healthcare profes-
sionals also provided feedback on how the PtDA could
be delivered in usual general practice. Their major con-
cerns were time constraints and a lack of familiarity with
the use of the PtDA, which were addressed by conduct-
ing a training workshop for the healthcare professionals
before they use it with their patients. This feedback was
discussed during the meetings with the review panel and
a concerted effort was made to incorporate these feed-
back into the final PtDA and its delivery.
Finalising the PTDA
The expert panel met four times during the review/revision
process to discuss the feedback from the patients and thehealthcare professionals based on the findings from the in-
depth interview analysis and “acceptability” questionnaire
surveys. The key findings were summarised and sent to the
expert panel at least one week in advance. During the sub-
sequent meetings, each member took turns to comment on
each section of the PtDA as well as the findings from the
in-depth interviews in order to achieve a consensus.
The PtDA was also revised in turn by the research team
based on the analysis of the interviews and the consensus
of the review panel meetings. This reviewing-revising it-
erative process was terminated when there were no fur-
ther comments emerging from users’ interviews and review
panel meetings.
The final draft was internally assessed using the IPDAS
quality criteria checklist and proof read before sending for
graphic design and printing. We found that the PANDAs
PtDA satisfied all the criteria of the IPDAS checklist. This
was the final step in the development of the PtDA before
it was subjected to formal evaluation.
Discussion
The development of the PANDAs PtDA demonstrates
that it is feasible to use a combination of the IPDAS and
the UKMRC frameworks to develop a PtDA based on
users’ needs, evidence and theories (ODSF). The IPDAS
recommendations provided evidence-based guidance on
the development of the content and structure of the
PtDA; the users’ healthcare decisional, social and emo-
tional needs informed the selection of the content; and
the ODSF provided a theoretical basis to link the devel-
opment of the PtDA to the outcome measures for evalu-
ation. Finally, the UKMRC framework for developing
and evaluating complex interventions in Primary Care
provided an overarching framework to guide the itera-
tive process, inform the choice of research methods and
ensure that the PtDA could be successfully developed,
evaluated and implemented in practice.
The recent IPDAS collaboration evidence document
reviewed the PtDAs assessed in the latest Cochrane
Review [4] and found that only half of the PtDAs under-
went field testing with patients and clinicians in the ‘real
world’ and only 17% documented the method of reviewing
and synthesising clinical evidence [18]. It also highlighted
the fact that few PtDAs provide sufficient details to assess
whether or not they comply with the IPDAS criteria.
This study describes systematically how the IPDAS cri-
teria guided the development of the PANDAs PtDA. The
use of a theoretical framework to develop PtDAs was not
part of the IPDAS standards [6]. However in the recent up-
date on the IPDAS evidence document, the use of a theor-
etical framework to develop PtDAs has been proposed
[19]. Similarly, the UKMRC guidance on how to develop
complex interventions such as PtDAs also recommends
the use of theories, which help to describe, explain and
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number of clinical trials on PtDAs, a comparison between
PtDAs which have or do not have a theoretical framework,
is possible and the revised IPDAS standards on the evalu-
ation of PtDA quality can be used to address this task [20].
The decision on ‘what’ and ‘how much’ to include in a
PtDA is also a challenging one. Conventionally, PtDAs
have focussed on delivering accurate and balanced infor-
mation about the treatment options to patients ie empha-
sising the information needs [21]. However, increasingly,
there is growing evidence that people do not make deci-
sions based only on the information they receive [22].
Other considerations such as the availability of healthcare,
emotional and social support may also affect how patients
make decisions and it is, therefore, crucial that these needs
of patients are attended to during the decision making
process. In this study, the findings from the needs assess-
ment reinforces this.
When identifying the best evidence to be included in the
PtDA, we encountered a few difficulties. Firstly, there was
a lack of systematic reviews or trials comparing insulin
with ‘make no change’ or ‘lifestyle modification’. This is
because it would be unethical and unacceptable to com-
pare insulin therapy with no treatment in people with
uncontrolled diabetes. There is also a lack of trials com-
paring insulin with lifestyle changes as most of these trials
are funded by the pharmaceutical industry which have a
vested interest in promoting drug usage [23].
In addition, there are also substantial variations in the
reported outcomes of studies. For example, some studies
report hypoglycaemic episodes as the number of epi-
sodes per 100 person year, whilst others report outcomes
as “proportions of people experiencing hypoglycaemic
episodes over a year”. In addition, few clinical trials re-
port on outcomes that are important to patients, such as
‘symptom relief ’, which are relevant to patients when
making any sort of medical decision [24].
In the PANDAs PtDA a list of diabetic symptoms was
included and patients were asked to indicate whether or
not they had experienced any of the symptoms. Although
the evidence was, to some extent, lacking, “diabetic symp-
tom relief” was included the in the PtDA as this is advice
that is routinely given by healthcare professionals and it
has a plausible scientific basis. Future clinical trials should
routinely report outcomes that are clinically important
to patients.
In the PANDAs PtDA, the risks and benefits were
communicated to patients using the accepted principles
of risk communication such as using textual, number and
visual display to present risks; using natural frequencies
rather than percentages; and emphasising the interaction
between patients and healthcare professionals [25]. There
is an increasing recognition that people use both ana-
lytic and intuitive mechanisms to make decisions; so howpeople perceive risk may depend as much on logic and
systematic analysis as well as emotions and heuristics [26].
Concerns were also raised about the purpose of the
PtDA and whether it would be used to “convince” patients
to start insulin treatment. Thompson PB has raised the
same issue that risk communication might be used to en-
courage changes in peoples’ behaviour for the sake of pub-
lic health gain [27]. However, the aim of the PANDAs
PtDA was to help patients make a decision which was in-
formed and based on what was important to them and
this was achieved by ensuring that the risk communica-
tion tool was balanced, accurate and up to date.
The purpose of value clarification in the process of
shared decision making is to help patients recognise that
their values play an important role in decision making.
It also helps patients to determine which treatment op-
tion and its attributes are important to them and share
their values with the healthcare professionals and their
families [28].
In the PANDAs study, an explicit “balanced technique”
was used to help patients compare and indicate the rela-
tive importance of the treatment option as well as the
attributes of each option [17]. However, patients found
it difficult to answer the “negatively phrased” questions
(e.g. ‘how important is it to avoid weight gain?’), especially
when the response was also negative (eg ‘not important’).
This difficulty was compounded when they were required
to rate the importance (from ‘not important’ to ‘very im-
portant’). As a result, the questions asked in the value
clarification section of the PtDA were modified and the
response items were reduced to a yes/no option. It was
clear that the accuracy of response to the questions in the
PANDAs PtDA needed to be weighed against the ease of
answering the questions.
The PtDA was delivered in a booklet based on feed-
back from the patients, healthcare professionals and ex-
pert panel during the needs assessment study. PtDAs
can be developed in other formats including web-based
compact discs or digital versatile disc; audio book, com-
mon decision board and patient focus groups. Increasingly
web-based decision aids are preferred by developers. A
paper-based PtDA was chosen because both healthcare
professionals and patients during the feasibility study
found the paper-based PtDA acceptable and the PtDA
itself needed to be used by healthcare professionals and
patients together in a consultation. In addition, a paper
PtDA was portable and could be taken home as required
by the patient for further consideration and it does not re-
quire any equipment. Most of the target population for
the use of the PtDA were above 50 years of age and the
assumption which was made for the study was that the
majority of people in this age group prefer to use paper-
based tools and are generally less familiar with using
computers or the internet. However, this preference is
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surgeons in the UK found that more than half of the re-
spondents preferred a booklet as a PtDA to other media
such as web-based PtDA, CD/DVD and audiotape [30].
However, the disadvantages of using a paper-based
PtDA are that the latter requires printing and mailing
which may hinder wide dissemination and printing and
reprinting of the PtDA was costly. By comparison, devel-
oping a web-based PtDA often needs only a single pay-
ment for computer programming and web design in the
initial phase and maintenance and updating of a web-
based PtDA requires less cost than reprinting of the
paper-based PtDA.
Finally, web-based or computer-assisted PtDAs allow
data to be collected and, if needed, summarized - so that
it can be fed back to the patients and healthcare profes-
sionals, an advantage which paper-based PtDAs do not
have. Nevertheless, a patient decision aid, regardless of
the mode of delivery, only serves as a tool to facilitate
discussion on the decision; it is not meant to replace a
clinical consultation.
Strengths and limitations
Although the PANDAs PtDA was developed according
to the two frameworks and, as far as possible, based on
needs, evidence and theories, there were numerous chal-
lenges which we encountered during its development.
There was some overlap in the roles of the members
within the expert panels which had the potential of cre-
ating biases in the development process. However, both
panels acknowledge the potential biases. On the other
hand, it was found that there were strengths in dual
roles which, for example, helped to facilitate communi-
cation among members of the panel who were from very
diverse backgrounds.
Feldman-Stewart et al. (2007) [31] reported that pa-
tients are often not consulted about the information they
would like to be included in the PtDA [31]. The strength
of this study is that it involved users (both patients and
healthcare providers) throughout the development of the
PtDA using individual in-depth interviews, questionnaire
surveys and an expert consensus to assess users’ needs;
to draft and revise the PtDA; and to determine its ac-
ceptability and feasibility. The mixed methods approach
was used to help ‘triangulate’ the data and improve the
credibility of the development process [32].
Conclusions
This study has demonstrated the feasibility of the IPDAS
and the UKMRC frameworks for the development and
evaluation of a PtDA. The IPDAS guideline was useful
for informing the content, development and formatting
of the PtDA, while the UKMRC framework helped to
link the process of development with the evaluation andimplementation of a complex intervention. Both frame-
works are complementary and essential components to
guide the development and evaluation of future PtDAs.
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